Clinical trial designers lack transparent, validated simulation methods to accelerate trials while maintaining regulatory compliance

Pharmaceutical companies and clinical research organizations spend years and billions running trials, but current processes lack transparent simulation-guided decision-making frameworks that regulators accept. EU regulatory bodies haven't established clear methodological standards for incorporating simulations into trial design, forcing researchers to either ignore simulation benefits or navigate ambiguous legal territory. This creates a bottleneck where trials remain slow and expensive despite available technology that could make them faster, cheaper, and more reliable.